Affidea collaborates with b-rayZ in the realm of AI for breast imaging technology
Affidea, a leading pan-European provider of diagnostic imaging and specialist healthcare services, has announced a strategic partnership with b-rayZ, a pioneer in AI-powered breast imaging solutions [1]. This collaboration significantly advances breast cancer diagnostics and patient outcomes across Europe by integrating cutting-edge AI technology into Affidea’s extensive clinical network.
The partnership positions Affidea and b-rayZ to accelerate innovation across their network. According to Dr. Charles Niehaus, deputy CEO of Affidea, the collaboration is aimed at redefining breast cancer diagnostics [2]. Dr. Alessandro Roncacci, SVP and Chief Medical Officer at Affidea, mentioned that AI-powered solutions like b-rayZ's are revolutionising breast cancer diagnostics [3].
Cristina Rossi, CEO and founder of b-rayZ, stated that the company is deeply committed to preserving women's health and designing AI solutions to provide the highest level of diagnostic accuracy and efficiency, tailored to each woman's needs [4]. The investment by Affidea in b-rayZ's Series A extension further validates the alignment of their shared vision to transform breast cancer diagnostics [5].
Key impacts of this partnership include enhanced diagnostic precision, faster and more personalised imaging, and a geographical reach that ensures a standardised, high-quality diagnostic experience throughout Europe [1][3][4]. The AI technology is already implemented successfully in several Affidea centers, including Switzerland, Lithuania, and Spain, with plans for further expansion across Affidea’s 15-country network and 391 medical centers [1][3][4].
By investing in b-rayZ, Affidea demonstrates a strong commitment to leveraging state-of-the-art AI and Swiss medical expertise to improve early breast cancer detection rates, ultimately leading to better patient outcomes and higher survival rates [3][4]. The partnership also aims to integrate AI to enhance sub-specialty breast imaging, improve diagnostic accuracy, and optimise personalised screening pathways [6].
The strategic partnership between Affidea and b-rayZ strengthens b-rayZ's position in the industry and opens up valuable collaboration opportunities to accelerate product development, expand into new markets, and enhance customer offerings [7]. The integration of AI across their network is intended to ensure that women across Europe receive the most accurate and timely diagnoses possible, tailored to them [8].
In conclusion, this partnership between Affidea and b-rayZ not only revolutionises breast cancer diagnostics through AI innovation but also aligns with Affidea’s mission to provide premium, community-based cancer detection and treatment services at scale across Europe [2][3]. The partnership reinforces Affidea's mission to set new standards in patient care.
- This collaboration between Affidea and b-rayZ, focused on breast cancer diagnostics, is aimed at redefining patient care through the integration of artificial intelligence technology.
- The strategic partnership is intended to leverage the benefits of AI technology in medical-conditions like breast cancer, improving diagnostic accuracy and personalisation.
- The partnership's goal is to enhance health-and-wellness for women by providing AI-powered solutions tailored to breast cancer diagnostics, ultimately improving outcomes.
- By integrating AI-powered solutions into its extensive clinical network, Affidea aims to strengthen womens-health services across Europe, addressing the early detection of breast cancer and ensuring timely, high-quality diagnostics.
